Pharmacological treatment of panic disorder.

Abstract:

:Panic disorder has recently been recognized as a distinct sub-type of anxiety which may occur with or without phobic avoidance. Controlled prospective trials have demonstrated the efficacy of the tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of this disorder. The use of benzodiazepines and beta-blockers has been more controversial. Some preliminary studies assessing other pharmacological agents are available. Methodological problems limit the conclusions which may be drawn from available data.

authors

Judd FK,Norman TR,Burrows GD

doi

10.1097/00004850-198601000-00002

subject

Has Abstract

pub_date

1986-01-01 00:00:00

pages

3-16

issue

1

eissn

0268-1315

issn

1473-5857

journal_volume

1

pub_type

杂志文章,评审
  • Hyoscine for clozapine-induced hypersalivation: a double-blind, randomized, placebo-controlled cross-over trial.

    abstract::Clozapine is the only evidence-based antipsychotic for treatment-resistant schizophrenia. However, it has considerable side effects, limiting its usability and reducing patients' adherence. One of the most common and distressing side effects is hypersalivation, which can be debilitating, stigmatizing and potentially d...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000251

    authors: Segev A,Evans A,Hodsoll J,Whiskey E,Sheriff RS,Shergill S,MacCabe JH

    更新日期:2019-03-01 00:00:00

  • Comorbidities in social phobia.

    abstract::In a sample of 2096 consecutive primary care patients recruited in the Paris region, social phobia was a highly prevalent disorder (5.1%). The most frequent comorbid condition was depressive episode, which affected 70% of patients with social phobia of early onset (at less than 15 years of age), while the highest asso...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199710006-00004

    authors: Lecrubier Y,Weiller E

    更新日期:1997-10-01 00:00:00

  • Is amisulpride an 'atypical' atypical antipsychotic agent?

    abstract::Amisulpride is a novel antipsychotic with a pharmacological and clinical profile that differs from that of other atypical agents. Amisulpride is highly selective for dopamine D2/D3 receptor subtypes located in the limbic region, which is highly predictive of potent antipsychotic activity with a low potential to cause ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Lecrubier Y

    更新日期:2000-12-01 00:00:00

  • Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine.

    abstract::Most antidepressants in clinical use are believed to function by enhancing neurotransmission of serotonin [5-hydroxytryptamine (5-HT)] and/or norepinephrine (NE) via inhibition of neurotransmitter reuptake. Agents that affect reuptake of both 5-HT and NE (serotonin-norepinephrine reuptake inhibitors) have been postula...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/YIC.0b013e3282f41d7e

    authors: Trivedi MH,Desaiah D,Ossanna MJ,Pritchett YL,Brannan SK,Detke MJ

    更新日期:2008-05-01 00:00:00

  • Striking a balance between safety and efficacy: experience with the SSRI sertraline.

    abstract::Depression is a widespread and serious disorder inflicting an immeasurable toll on the lives of millions of people and affecting their families and colleagues. It is the cause of countless suicides especially in those whose illness has not been detected or given appropriate care. Until recently, effective pharmacother...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Casey DE

    更新日期:1994-06-01 00:00:00

  • Comparison of performance of healthy volunteers given prazepam alone or combined with ethanol. Relation to drug plasma concentrations.

    abstract::The interaction between a single dose of 20 mg of prazepam and 0.5 g/kg body weight ethanol was investigated in 12 healthy male volunteers by nine objective performance tests, eight visual analogue self-rating scales and measurement of prazepam and ethanol plasma concentrations, using a double-blind three-way crossove...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199100640-00004

    authors: Girre C,Hirschhorn M,Bertaux L,Palombo S,Fournier PE

    更新日期:1991-01-01 00:00:00

  • Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials.

    abstract::Small studies have shown positive effects from adding a variety of antipsychotic agents in patients with obsessive-compulsive disorder who are unresponsive to treatment with serotonin reuptake inhibitors. The evidence, however, is contradictory. This paper reports a meta-analysis of existing double-blind randomized pl...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/01.yic.0000215083.57801.11

    authors: Fineberg NA,Stein DJ,Premkumar P,Carey P,Sivakumaran T,Vythilingum B,Seedat S,Westenberg H,Denys D

    更新日期:2006-11-01 00:00:00

  • Refining treatment approaches in obsessive-compulsive disorder.

    abstract::Obsessive-compulsive disorder (OCD) has emerged as a common but frequently hidden psychiatric disorder which inflicts an intolerable burden on sufferers and demands effective management. For many years, however, OCD was considered treatment resistant and it is only in the past 15 years that effective therapy has becom...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199612005-00003

    authors: Fineberg N

    更新日期:1996-12-01 00:00:00

  • DIABCARE Quality Network in Europe--a model for quality management in chronic diseases.

    abstract::The DIABCARE Q-Net project developed a complete and integrated information technology system to monitor diabetes care, according to the gold standards of the St Vincent Declaration Action Program. This is the first Telematic platform for standardized documentation on medical quality and evaluation across Europe, which...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200104003-00002

    authors: Piwernetz K

    更新日期:2001-04-01 00:00:00

  • Resurrecting the discussion on neurotoxicity of lithium at therapeutic levels.

    abstract::Lithium is widely used in the treatment of bipolar disorder. Here we describe the syndrome of irreversible lithium-effectuated neurotoxicity in a patient within therapeutic doses and levels, which persisted after discontinuation of Lithium. A 50-year-old gentleman with Bipolar disorder presented with symptoms of Mania...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000341

    authors: Jha A,Pai NM,Ganjekar S,Desai G,Chaturvedi SK

    更新日期:2021-03-01 00:00:00

  • Early onset of action of amineptine.

    abstract::A priority in the treatment of depression is to obtain rapid improvement at an early stage. Since depressed patients, who are often convinced that nothing can be done for them, may well have difficulty in adhering to the therapeutic management plan, they can be both uncooperative and neglectful of treatment measures. ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199707003-00005

    authors: Freeman H

    更新日期:1997-07-01 00:00:00

  • Prescribing patterns of lithium or lithium+valproate in manic or mixed episodes: a naturalistic study.

    abstract::The present study aimed to identify the prescribing patterns of lithium or of lithium+valproate in 75 bipolar I outpatients in a manic or a mixed phase within a naturalistic setting. The differences between the two treatments and the correlation between serum lithium levels and response were also examined. The results...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e3283642348

    authors: Muti M,Del Grande C,Musetti L,Marazziti D,Pergentini I,Corsi M,Turri M,Umberto Corsini G,Dell'Osso L

    更新日期:2013-11-01 00:00:00

  • Effects of risperidone on affective symptoms in patients with schizophrenia.

    abstract::The effects of risperidone on affective symptoms were determined by an analysis of pooled data from six double-blind trials of risperidone versus haloperidol in 1254 patients with chronic schizophrenia. Symptoms indicating mania were assessed by the Positive and Negative Syndrome Scale (PANSS) excitement and grandiosi...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/00004850-200015060-00005

    authors: Peuskens J,Van Baelen B,De Smedt C,Lemmens P

    更新日期:2000-11-01 00:00:00

  • Antidepressant interactions with warfarin.

    abstract::The interactions between warfarin and antidepressants can have potentially serious consequences resulting from enhanced or reduced anticoagulant activity. Information about such interactions was obtained from a Medline and hand search of the published literature, and by directly contacting manufacturers. The different...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199803000-00006

    authors: Duncan D,Sayal K,McConnell H,Taylor D

    更新日期:1998-03-01 00:00:00

  • A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group.

    abstract::Quetiapine ('Seroquel') is a well-tolerated, novel, atypical antipsychotic with consistent efficacy in the treatment of schizophrenia. To date, no clinical studies have evaluated the effect of quetiapine in patients who only partially respond to conventional antipsychotics, yet this type of patient is most frequently ...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/00004850-200015030-00001

    authors: Emsley RA,Raniwalla J,Bailey PJ,Jones AM

    更新日期:2000-05-01 00:00:00

  • The conundrum of depression clinical trials: one size does not fit all.

    abstract::In this paper we review the history of antidepressant (AD) development, since the discovery of imipramine in 1957 to the present day. Through this exploration we will show that the increasing placebo response is likely a red herring and that a higher magnitude of placebo response is not an adequate explanation for AD ...

    journal_title:International clinical psychopharmacology

    pub_type: 历史文章,杂志文章,评审

    doi:10.1097/YIC.0000000000000229

    authors: Khan A,Mar KF,Brown WA

    更新日期:2018-09-01 00:00:00

  • Clozapine-associated neutropenia in Latin America: incidence report of 5380 Chilean users.

    abstract::Systematic information about Latino clozapine users is still scarce. Our aim was to evaluate the risk of clozapine-associated neutropenia in a Chilean cohort using the last Food and Drug Administration's recommendations for clozapine monitoring. Findings should improve clinical practice and promote changes in clozapin...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000270

    authors: Mena CI,Nachar RA,Crossley NA,González-Valderrama AA

    更新日期:2019-09-01 00:00:00

  • The effects of moclobemide on psychomotor performance and cognitive function.

    abstract::Sixteen young male volunteers received single doses of moclobemide 200 mg, moclobemide 400 mg, amitriptyline 50 mg and placebo in a double-blind crossover study. Subjects then completed a test battery which is sensitive to the effects of psychoactive drugs at 1, 2, and 4 h post-dose. The test battery included tasks of...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199300810-00007

    authors: Fairweather DB,Kerr JS,Hindmarch I

    更新日期:1993-04-01 00:00:00

  • Serotonin: current understanding and the way forward.

    abstract::Serotonin is a key neurotransmitter in the central nervous system. In recent years its role in the pathophysiology and pharmacology of depression has been extensively investigated. Neuroendocrine studies suggest decreased serotonergic responsivity in patients with major depression. The fact that the majority of patien...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Dinan TG

    更新日期:1996-03-01 00:00:00

  • Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment.

    abstract::Recent evidence has demonstrated the efficacy of pegylated interferon-alpha (IFN-alpha) in treating hepatitis C virus infection. Neuropsychiatric complications commonly occur during the course of IFN treatment, with depressive symptoms usually appearing within the first 12 weeks. Few cases of the pegylated interferon-...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.yic.0000170263.46008.54

    authors: Sockalingam S,Balderson K

    更新日期:2005-09-01 00:00:00

  • Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor-Davidson Resilience Scale.

    abstract::The aim was to evaluate the efficacy of venlafaxine extended release (ER) on characteristics of resilience, measured by the Connor-Davidson Resilience Scale, in patients with posttraumatic stress disorder (PTSD). Data were evaluated from a randomized, 6-month, international, multicenter study of adult outpatients with...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/YIC.0b013e32830c202d

    authors: Davidson J,Baldwin DS,Stein DJ,Pedersen R,Ahmed S,Musgnung J,Benattia I,Rothbaum BO

    更新日期:2008-09-01 00:00:00

  • A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed.

    abstract::While most depressed patients are prescribed a selective serotonin reuptake inhibitor (SSRI) as an initial treatment, the use of SSRIs as a second or third-line treatment for depression is not as prevalent. This trial assessed the efficacy of sertraline for patients with treatment-resistant depression (TRD) or patient...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-200309000-00006

    authors: Papakostas GI,Petersen T,Worthington JJ,Roffi PA,Alpert JE,Fava M,Nierenberg AA

    更新日期:2003-09-01 00:00:00

  • Socioeconomic factors influencing antipsychotic prescription for schizophrenia inpatients in China: a cross-sectional study.

    abstract::Medication is critical in schizophrenia therapy, and prescription patterns have changed considerably over the past 20 years in China. This study attempts to evaluate the prescription patterns of antipsychotics for inpatients with schizophrenia in China and to identify factors influencing these patterns. Claims data of...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000024

    authors: Xue Q,Xiong X,Feng Y,Yao L,Chen S,Xiang L

    更新日期:2014-09-01 00:00:00

  • Toleration and safety of sertraline: experience worldwide.

    abstract::The clinical trial programme of sertraline, a selective serotonin re-uptake inhibitor, has shown the drug to have a favourable safety and toleration profile. In contrast, the tricyclic antidepressant, amitriptyline, produced a significant level of side effects, particularly anticholinergic. The side-effect profile of ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199112002-00007

    authors: Doogan DP

    更新日期:1991-12-01 00:00:00

  • Do continued antidepressants protect against dementia in patients with severe depressive disorder?

    abstract::Studies on humans show that depressive disorder is associated with an increased risk of developing cognitive dysfunction, and animal studies suggest that antidepressants may have neuroprotective abilities. On the basis of these observations, it was hypothesized that treatment with antidepressants may decrease the risk...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e32834ace0f

    authors: Kessing LV,Forman JL,Andersen PK

    更新日期:2011-11-01 00:00:00

  • Antipsychotic drug--a study of the prescription pattern in a total sample of patients with a schizophrenic syndrome in one catchment area in the county of Uppland, Sweden, in 1991.

    abstract::In a total population of patients with a schizophrenic syndrome, the amount of antipsychotic drugs during a defined period was studied. Doses of antipsychotics were higher in males than in females, low to moderate in most patients, and decreased with the duration of illness. There was a significant negative correlatio...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199612000-00005

    authors: Lindström E,Widerlöv B,von Knorring L

    更新日期:1996-12-01 00:00:00

  • Carbamazepine compared to haloperidol in acute mania.

    abstract::In a double-blind, between-patient clinical trial carbamazepine (CBZ) (n = 8) was compared to haloperidol (HP) (n = 9) in patients presenting with mania (DSM III). Seven patients on HP and 2 on CBZ failed to complete 4 weeks treatment. In 4 of the HP group this was because of extrapyramidal side-effects (EPS). Two pat...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-198907000-00005

    authors: Brown D,Silverstone T,Cookson J

    更新日期:1989-07-01 00:00:00

  • Prediction of response to acute neuroleptic treatment in schizophrenia.

    abstract::Predicting the outcome of treatment with neuroleptics and understanding the factors that contribute to variability in the response to these drugs have preoccupied researchers and clinicians since the class was developed. Clinicians need empirically based prospective criteria in order to choose a treatment strategy tha...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199605002-00008

    authors: Gaebel W

    更新日期:1996-05-01 00:00:00

  • Anticholinergic equivalents and parkinsonism: a model for predicting side-effects of antipsychotic drugs.

    abstract::The tendency of antipsychotics to produce extrapyramidal side-effects varies inversely with their antimuscarinic activity. This paper reviews the antipsychotic and antimuscarinic potency of these drugs and compares the total antimuscarinic activity in standard daily doses of antipsychotics, antiparkinson agents and an...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-198701000-00005

    authors: Menkes DB,Clarkson HO,Caradoc-Davies G,Mullen PE

    更新日期:1987-01-01 00:00:00

  • Anxiogenic effect of yohimbine in healthy subjects: comparison with caffeine and antagonism by clonidine and diazepam.

    abstract::Three placebo-controlled double-blind and crossover trials were carried out to analyze the effects of oral yohimbine (YOH) 0.8 mg/kg on mood and performance in 16 healthy students. Subjective assessments (visual analogue scales, side-effects on questionnaire) and objective measurements (digit symbols, flicker fusion, ...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-198807000-00003

    authors: Mattila M,Seppala T,Mattila MJ

    更新日期:1988-07-01 00:00:00